Home UAE Abu Dhabi Abu Dhabi’s Mubadala and Kohlberg acquire majority stake in PCI Pharma Services Philadelphia-based PCI provides a range of integrated pharmaceutical supply chain solutions by Varun Godinho August 25, 2020 Abu Dhabi-based Mubadala Investment Company (Mubadala) and New York-headquartered private equity firm Kohlberg & Company (Kohlberg) will acquire a majority stake in Philadelphia-based pharmaceutical and biopharmaceutical global supply chain solutions provider, and portfolio company of Partners Group, PCI Pharma Services (PCI). Partners Group agreed to the sale of its majority equity stake in PCI on behalf of its clients and alongside its consortium partners Thomas H. Lee Partners and Frazier Healthcare Partners. أعلنّا عن توقيع اتفاقية إلى جانب شركة “كولبيرج” للاستحواذ على حصة أغلبية في شركة “بي سي آي” للخدمات الدوائية وهي شركة رائدة مختصة في حلول سلسلة التوريد العالمية لقطاع الأدوية والأدوية الحيوية وجزء من محفظة شركات مجموعة “بارتنرز”. pic.twitter.com/wf5mbXS9tZ — Mubadala (@Mubadala) August 24, 2020 Partners Group will however retain a minority equity stake in PCI. The terms of the transaction are not disclosed, reported news agency WAM. “Outsourced pharmaceutical services has been a key investment theme for us over the past few years, and we are excited to be partnering with one of the global leaders in this industry. We have been particularly impressed by the quality and depth of PCI’s management team, as well as the company’s strong execution track record, impeccable values, and distinct vision for the long-term development of their business,” said Camilla Macapili Languille, head of Pharma and Medtech, Mubadala. Read: UAE’s Julphar announces 90% increase in revenues for Q2 2020 PCI provides a range of integrated pharmaceutical supply chain solutions from the early stages drug development through to commercial launch and delivering ongoing supply with global capabilities for drug development and manufacturing, clinical trials services and commercial packaging services. It has a footprint of 25 GMP facilities across six countries and employs 3,900 people worldwide. “PCI teams have embarked on a purposeful journey over recent years to transform the company by executing a successful growth strategy providing customers with innovative and integrated supply chain solutions with the industry-leading customer experience by differentiating through investment in global capabilities, operational excellence, technology and our biggest asset, our talented people”, said Salim Haffar, PCI’s CEO. Tags Camilla Macapili Languille Healthcare Kohlberg Mubadala PCI Pharma Services pharmaceutical UAE 0 Comments You might also like UAE’s Julphar divests Zahrat Al Rawdah Pharmacies Abu Dhabi launches new licencing framework for longevity medicine centres Last chance for UAE overstayers as visa amnesty deadline extended Building a tech empire: Jumbo Electronics Ltd.’s CEO on 50 years of growth